Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 8/20 | 0.38 |
| ▸ | CTSB | P07858 | 7/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13016822 | 1.00 | CA12 (0.45) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13016845 | 0.92 | CA12 (0.45) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13016818 | 0.90 | TMEM97 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3104786 | 0.90 | TMEM97 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3118589 | 0.85 | TMEM97 (0.44) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13016803 | 0.85 | TMEM97 (0.44) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13062728 | 0.85 | HTT (0.35) | CTSLCTSBHTTALDH1A1CTSS | |
| SCHEMBL13016815 | 0.85 | ALDH1A1 (0.37) | CTSLCTSBALDH1A1 | |
| SCHEMBL3116579 | 0.85 | ALDH1A1 (0.37) | CTSLCTSBALDH1A1 | |
| SCHEMBL13016814 | 0.83 | CACNA2D1 (0.40) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | CA12 3316/4885CA1 1813/4885CA2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.